Structure Therapeutics Inc. (GPCR)
| Market Cap | 817.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -40.01M |
| Shares Out | 36.59M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 89,662 |
| Open | 21.99 |
| Previous Close | 21.21 |
| Day's Range | 21.58 - 23.55 |
| 52-Week Range | 20.80 - 30.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 40.04 (+79.15%) |
| Earnings Date | n/a |
About GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular dis... [Read more]
Financial Performance
Financial StatementsNews
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therape...
Structure Therapeutics IPO prices at top of range with larger number of shares added in a sign of healthy investor interest
Structure Therapeutics Inc. GPCR, priced 10.74 million American depositary shares at $15 each to raise $161 million in its initial public offering with joint book-running managers Jefferies, SVB Secur...
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule ...
Structure Therapeutics sets IPO terms, to be valued at up to $522 million
Structure Therapeutics Inc. has set terms for its initial public offering (IPO), as the California-based biopharmaceutical company developing oral therapeutics looks to raise up to $134.25 million. Th...
Chronic disease biotech Structure Therapeutics files for a $100 million IPO
Structure Therapeutics, a Phase 1 biotech developing G-protein-coupled receptors for chronic diseases, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
Structure Therapeutics IPO Registration Document (S-1)
Structure Therapeutics has filed to go public with an IPO on the {Market}.